India’s Sun Pharma to buy Checkpoint Therapeutics for $355 mln

Investing.com

10小時前

Investing.com-- Sun Pharmaceutical (TADAWUL:2070) Industries Ltd. (NSE:SUN) said on Monday that it will buy Checkpoint Therapeutics Inc (NASDAQ:CKPT)- a Nasdaq-listed immunotherapy and oncology firm- for about $355 million.

Sun said it will offer $4.10 in cash for each share in Checkpoint, a nearly 66% premium to Checkpoint’s Friday close of $2.470. Checkpoint shareholders will also receive a commitment for an additional $0.70 per share if the company’s cosbelimab treatment is approved in Europe prior to certain deadlines.

Cosibelimab- which is Checkpoint’s FDA-approved treatment for certain variants of skin cancer- is the key motivator behind Sun’s bid, with the Indian pharmaceutical firm stating that the deal will introduce Checkpoint’s treatment across more countries.

The deal is expected to be completed in the second quarter of 2025.

Sun has also entered into a royalty agreement with Fortress Biotech Inc (NASDAQ:FBIO), Checkpoint’s controlling shareholder, under which the latter will receive payments based on future sales of cosibelimab.

Sun Pharma was founded in 1983 and is one of the world’s biggest manufacturers of generic pharmaceuticals, which are also a major export product for India. The company has diversified into a wide range of healthcare services in recent years, and offers services in over 100 countries.

Related Articles

India’s Sun Pharma to buy Checkpoint Therapeutics for $355 mln

Trump says government shutdown is possible, but expects to avert it

Seven & i in talks with Couche-Tard over store sales for merger deal

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2518250530"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2518250530\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2518250530?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-10 11:13","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2518250530","market":"us","top_or_hot":-1,"title":"India’s Sun Pharma to buy Checkpoint Therapeutics for $355 mln","media":"Investing.com","content":"<html><body><p>Investing.com-- Sun Pharmaceutical (TADAWUL:2070) Industries Ltd. (NSE:SUN) said on Monday that it will buy Checkpoint <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc (NASDAQ:CKPT)- a Nasdaq-listed immunotherapy and oncology firm- for about $355 million. </p>\n<p dir=\"ltr\">Sun said it will offer $4.10 in cash for each share in Checkpoint, a nearly 66% premium to Checkpoint’s Friday close of $2.470. Checkpoint shareholders will also receive a commitment for an additional $0.70 per share if the company’s cosbelimab treatment is approved in Europe prior to certain deadlines. </p>\n<p dir=\"ltr\">Cosibelimab- which is Checkpoint’s FDA-approved treatment for certain variants of skin cancer- is the key motivator behind Sun’s bid, with the Indian pharmaceutical firm stating that the deal will introduce Checkpoint’s treatment across more countries. </p>\n<p dir=\"ltr\">The deal is expected to be completed in the second quarter of 2025. </p>\n<p dir=\"ltr\">Sun has also entered into a royalty agreement with Fortress Biotech Inc (NASDAQ:FBIO), Checkpoint’s controlling shareholder, under which the latter will receive payments based on future sales of cosibelimab. </p>\n<p dir=\"ltr\">Sun Pharma was founded in 1983 and is one of the world’s biggest manufacturers of generic pharmaceuticals, which are also a major export product for India. The company has diversified into a wide range of healthcare services in recent years, and offers services in over 100 countries. </p>\n<p>Related Articles</p>\n<p>India’s Sun Pharma to buy Checkpoint Therapeutics for $355 mln</p>\n<p>Trump says government shutdown is possible, but expects to avert it</p>\n<p>Seven & i in talks with Couche-Tard over store sales for merger deal</p>\n</body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>India’s Sun Pharma to buy Checkpoint Therapeutics for $355 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIndia’s Sun Pharma to buy Checkpoint Therapeutics for $355 mln\n</h2>\n<h4 class=\"meta\">\n</h4><p class=\"head\">\n<strong class=\"h-name small\">Investing.com</strong><span class=\"h-time small\">2025-03-10 11:13</span>\n</p>\n</header>\n<article>\n<p>Investing.com-- Sun Pharmaceutical (TADAWUL:2070) Industries Ltd. (NSE:SUN) said on Monday that it will buy Checkpoint <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc (NASDAQ:CKPT)- a Nasdaq-listed immunotherapy and oncology firm- for about $355 million. </p>\n<p dir=\"ltr\">Sun said it will offer $4.10 in cash for each share in Checkpoint, a nearly 66% premium to Checkpoint’s Friday close of $2.470. Checkpoint shareholders will also receive a commitment for an additional $0.70 per share if the company’s cosbelimab treatment is approved in Europe prior to certain deadlines. </p>\n<p dir=\"ltr\">Cosibelimab- which is Checkpoint’s FDA-approved treatment for certain variants of skin cancer- is the key motivator behind Sun’s bid, with the Indian pharmaceutical firm stating that the deal will introduce Checkpoint’s treatment across more countries. </p>\n<p dir=\"ltr\">The deal is expected to be completed in the second quarter of 2025. </p>\n<p dir=\"ltr\">Sun has also entered into a royalty agreement with Fortress Biotech Inc (NASDAQ:FBIO), Checkpoint’s controlling shareholder, under which the latter will receive payments based on future sales of cosibelimab. </p>\n<p dir=\"ltr\">Sun Pharma was founded in 1983 and is one of the world’s biggest manufacturers of generic pharmaceuticals, which are also a major export product for India. The company has diversified into a wide range of healthcare services in recent years, and offers services in over 100 countries. </p>\n<p>Related Articles</p>\n<p>India’s Sun Pharma to buy Checkpoint Therapeutics for $355 mln</p>\n<p>Trump says government shutdown is possible, but expects to avert it</p>\n<p>Seven & i in talks with Couche-Tard over store sales for merger deal</p>\n<div class=\"bt-text\">\n<p> 來源：<a href=\"https://finance.yahoo.com/news/india-sun-pharma-buy-checkpoint-031303490.html\">Investing.com</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"USJW.SI","symbol_name":"ALPHAB 3xLongSG261006","start_time":0,"source_url":"https://finance.yahoo.com/news/india-sun-pharma-buy-checkpoint-031303490.html","article_id":"2518250530","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2518250530","pubTimestamp":1741576383,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Investing.com--Sun Pharmaceutical  Industries Ltd.  said on Monday that it will buy Checkpoint Therapeutics Inc - a Nasdaq-listed immunotherapy and oncology firm- for about $355 million.Sun said it will offer $4.10 in cash for each share in Checkpoint, a nearly 66% premium to Checkpoint’s Friday close of $2.470. Checkpoint shareholders will also receive a commitment for an additional $0.70 per share if the company’s cosbelimab treatment is approved in Europe prior to certain deadlines.Cosibelimab- which is Checkpoint’s FDA-approved treatment for certain variants of skin cancer- is the key motivator behind Sun’s bid, with the Indian pharmaceutical firm stating that the deal will introduce Checkpoint’s treatment across more countries.The deal is expected to be completed in the second quarter of 2025.Sun has also entered into a royalty agreement with Fortress Biotech Inc , Checkpoint’s controlling shareholder, under which the latter will receive payments based on future sales of cosibelim","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"USJW.SI":"ALPHAB 3xLongSG261006","LENZ":"Therapeutics","NVIW.SI":"NVDA 3xLongSG261006",".IXIC":"NASDAQ Composite","CKPT":"Checkpoint Therapeutics, Inc.","SQQQ":"纳指三倍做空ETF","FBIO":"Fortress Biotech Inc.","PSQ":"纳指反向ETF","BK4139":"生物科技","USAW.SI":"AMZN 3xLongSG261006","QID":"纳指两倍做空ETF","TSYW.SI":"TESLA 3xLongSG261006","QLD":"纳指两倍做多ETF","TQQQ":"纳指三倍做多ETF"},"translate_title":"印度Sun Pharma将以3.55亿美元收购Checkpoint Therapeutics","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FBIO":1,"LENZ":1,"CKPT":0.9,".IXIC":0.72,"MNQmain":0.6,"NQmain":0.6,"NVIW.SI":0.6,"PSQ":0.6,"QID":0.6,"QLD":0.6,"SQQQ":0.6,"TQQQ":0.6,"TSYW.SI":0.6,"USAW.SI":0.6,"USJW.SI":0.6},"content_text":"Investing.com-- Sun Pharmaceutical (TADAWUL:2070) Industries Ltd. (NSE:SUN) said on Monday that it will buy Checkpoint Therapeutics Inc (NASDAQ:CKPT)- a Nasdaq-listed immunotherapy and oncology firm- for about $355 million. \nSun said it will offer $4.10 in cash for each share in Checkpoint, a nearly 66% premium to Checkpoint’s Friday close of $2.470. Checkpoint shareholders will also receive a commitment for an additional $0.70 per share if the company’s cosbelimab treatment is approved in Europe prior to certain deadlines. \nCosibelimab- which is Checkpoint’s FDA-approved treatment for certain variants of skin cancer- is the key motivator behind Sun’s bid, with the Indian pharmaceutical firm stating that the deal will introduce Checkpoint’s treatment across more countries. \nThe deal is expected to be completed in the second quarter of 2025. \nSun has also entered into a royalty agreement with Fortress Biotech Inc (NASDAQ:FBIO), Checkpoint’s controlling shareholder, under which the latter will receive payments based on future sales of cosibelimab. \nSun Pharma was founded in 1983 and is one of the world’s biggest manufacturers of generic pharmaceuticals, which are also a major export product for India. The company has diversified into a wide range of healthcare services in recent years, and offers services in over 100 countries. \nRelated Articles\nIndia’s Sun Pharma to buy Checkpoint Therapeutics for $355 mln\nTrump says government shutdown is possible, but expects to avert it\nSeven & i in talks with Couche-Tard over store sales for merger deal","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0}}}